Clinical Trials Logo
  1. Home
  2. Poor Graft Function
  3. NCT05907499

Decitabine for Poor Graft Function Post Allo-HSCT

Poor Graft Function Clinical Trial

Official title:
Low Dose Decitabine for Poor Graft Function Post Allogenic Hematopoietic Stem Cell Transplantation

Clinical Trial Summary

This randomized trial aims at validating the efficacy and safety of low-dose decitabine for PGF post allo-HSCT.

Clinical Trial Description

Poor graft function (PGF), defined by the presence of multilineage cytopenias in the presence of 100% donor chimerism, is a serious complication of allogeneic stem cell transplant (allo-HSCT). Emerging evidence demonstrates that the inadequate stem cells infusion, bone marrow microenvironment and immune dysregulation play a crucial role in maintaining and regulating hematopoiesis. Current therapies remain debatable, including selected CD34+ cells infusion, mesenchymal stromal cells infusion, prophylactic N-acetyl cysteine administration, etc. Thereafter, the investigators conduct a randomized trial aiming at validating the efficacy and safety of low-dose decitabine in PGF post allo-HSCT patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05907499
Study type Interventional
Source The First Affiliated Hospital of Soochow University
Contact Yaqiong Tang, Doctor
Phone 18896588075
Email tangyaqiong@suda.edu.cn
Status Not yet recruiting
Phase Phase 3
Start date July 1, 2023
Completion date November 1, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02240992 - MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment Phase 2/Phase 3
Completed NCT01857336 - G-CSF Moblized Peripheral Harvest for Poor Engraftment After Stem Cell Transplantation N/A
Recruiting NCT02083718 - Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function Phase 2
Recruiting NCT01763086 - Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant Phase 2
Recruiting NCT00603330 - Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function Phase 2
Not yet recruiting NCT03437603 - Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Terminated NCT03718533 - Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function Phase 2
Not yet recruiting NCT05669079 - Decitabine and Umbilical Cord Blood for Poor Graft Function Post Allo-HSCT Phase 3